Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.

Fusions of the RET and ROS1 protein tyrosine kinase oncogenes with several partner genes were recently identified as new targetable genetic aberrations in cases of non-small cell lung cancer (NSCLC) lacking activating EGFR, KRAS, ALK, BRAF, or HER2 oncogene aberrations. RET and ROS1 fusion-positive tumors are mainly observed in young, female, and/or never smoking patients. Studies based on in vitro and in vivo (i.e., mouse) models and studies of several fusion-positive patients indicate that inhibiting the kinase activity of the RET and ROS1 fusion proteins is a promising therapeutic strategy. Accordingly, there are several ongoing clinical trials aimed at examining the efficacy of tyrosine kinase inhibitors (TKIs) against RET and ROS1 proteins in patients with fusion-positive lung cancer. Other gene fusions (NTRK1, NRG1, and FGFR1/2/3) that are targetable by existing TKIs have also been identified in NSCLCs. Options for personalized lung cancer therapy will be increased with the help of multiplex diagnosis systems able to detect multiple druggable gene fusions.

[1]  Shibing Deng,et al.  A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. , 2014, The Journal of molecular diagnostics : JMD.

[2]  P. Jänne,et al.  The quest to overcome resistance to EGFR-targeted therapies in cancer , 2013, Nature Medicine.

[3]  Koichi Goto,et al.  RET fusion gene: Translation to personalized lung cancer therapy , 2013, Cancer science.

[4]  T. Kohno,et al.  RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis , 2014, British Journal of Cancer.

[5]  Y. Nakanishi,et al.  Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer , 2014, OncoTargets and therapy.

[6]  S. Ren,et al.  Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples , 2014, Translational oncology.

[7]  A. Yoshizawa,et al.  Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  D. Brat,et al.  Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.

[9]  Yasushi Totoki,et al.  KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.

[10]  Koji Tsuta,et al.  Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma , 2014, Clinical Cancer Research.

[11]  S. Aebi,et al.  A patient with lung adenocarcinoma and RET fusion treated with vandetanib. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  T. Kohno,et al.  Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers , 2014, Modern Pathology.

[13]  Seungbok Lee,et al.  A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. , 2012, Genome research.

[14]  S. Ou,et al.  Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally? , 2014, Front. Oncol..

[15]  P. Jänne,et al.  New targetable oncogenes in non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Mari Mino-Kenudson,et al.  Acquired resistance to crizotinib from a mutation in CD74-ROS1. , 2013, The New England journal of medicine.

[17]  L. Garraway,et al.  Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.

[18]  T. Kohno,et al.  ROS1-Rearranged Lung Cancer: A Clinicopathologic and Molecular Study of 15 Surgical Cases , 2013, The American journal of surgical pathology.

[19]  H. Ji,et al.  RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Nickolay A. Khazanov,et al.  Identification of targetable FGFR gene fusions in diverse cancers. , 2013, Cancer discovery.

[21]  Yih-Leong Chang,et al.  Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case , 2014, Medical Oncology.

[22]  J. Doroshow,et al.  Molecular analysis for therapy choice: NCI MATCH. , 2014, Seminars in oncology.

[23]  Yutaka Suzuki,et al.  Identification of a lung adenocarcinoma cell line with CCDC6‐RET fusion gene and the effect of RET inhibitors in vitro and in vivo , 2013, Cancer science.

[24]  K. Kumamoto,et al.  A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis. , 2014, Carcinogenesis.

[25]  Lei Wang,et al.  ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. , 2014, Lung cancer.

[26]  Hiroyuki Aburatani,et al.  Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  H. Asamura,et al.  The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. , 2013, Lung cancer.

[28]  Jeffrey W. Clark,et al.  ROS1 rearrangements define a unique molecular class of lung cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Doron Lipson,et al.  Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies , 2012, Nature Medicine.

[30]  F. Cappuzzo,et al.  Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[31]  W. Pao,et al.  Chipping away at the lung cancer genome , 2012, Nature Medicine.

[32]  A. Iafrate,et al.  Anchored multiplex PCR for targeted next-generation sequencing , 2014, Nature Medicine.

[33]  A. Marchetti,et al.  Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. , 2014, Clinical lung cancer.

[34]  R. Bernards,et al.  Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing , 2013, The Journal of pathology.

[35]  Tianhong Li,et al.  Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Koji Tsuta,et al.  Molecular Mechanisms Underlying Oncogenic RET Fusion in Lung Adenocarcinoma , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[37]  Chandra Sekhar Pedamallu,et al.  Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. , 2013, Cancer research.

[38]  T. Gu,et al.  Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non–Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion , 2012, Clinical Cancer Research.

[39]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[40]  Lei Wang,et al.  FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer , 2014, Clinical Cancer Research.

[41]  Yi-Song Wang,et al.  Response to crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  R. Doebele,et al.  Molecular Pathways Molecular Pathways : ROS 1 Fusion Proteins in Cancer , 2013 .

[43]  L. Mulligan.  RET revisited: expanding the oncogenic portfolio , 2014, Nature Reviews Cancer.

[44]  Y. Totoki,et al.  Mouse Model for ROS1-Rearranged Lung Cancer , 2013, PloS one.

[45]  D. Maintz,et al.  Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. , 2013, Lung cancer.

[46]  Yoo Jin Jung,et al.  The transcriptional landscape and mutational profile of lung adenocarcinoma , 2012, Genome research.

[47]  Lu Wang,et al.  Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. , 2013, Cancer discovery.

[48]  I. Petersen,et al.  CD74-NRG1 fusions in lung adenocarcinoma. , 2014, Cancer discovery.

[49]  J. Engelman,et al.  ALK in lung cancer: past, present, and future. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  I. Petersen,et al.  Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.

[51]  Yih-Leong Chang,et al.  Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[52]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[53]  Yuki Togashi,et al.  RET, ROS1 and ALK fusions in lung cancer , 2012, Nature Medicine.